Jeff Sorenson

Jeff Sorenson

CEO and co-founder, Yunu

Latest Stories
Sponsored
Imaging assessments are a requirement for most oncology trial endpoints. Yet, many cancer centers are still trying to support research trials with clinical care tools and ad hoc processes that are not fit-for-purpose and don’t meet the needs of sponsors or trial staff. 
Sponsored
In cancer care, imaging has become a marvel of modern medicine. Advances in scanner technology, reconstruction algorithms, contrast agents, and diagnostic protocols have radically improved our ability to detect, track, and understand disease. Clinically, imaging is fast, accurate, and central to decision-making. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login